The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche
Giada Bianchi(Brigham and Women's Hospital), Kenneth C. Anderson(Dana-Farber Cancer Institute), Yu‐Tzu Tai(Harvard University), Irene M. Ghobrial(Dana-Farber Cancer Institute), Ruben D. Carrasco(Brigham and Women's Hospital), Peter G. Czarnecki(Beth Israel Deaconess Medical Center), Yawara Kawano(Kumamoto University Hospital), Kenneth Wen(Dana-Farber Cancer Institute), Anıl Aktaş Samur(Harvard University), Gulden Camci‐Unal(University of Massachusetts Lowell), Aldo M. Roccaro(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Annamaria Gullà(Candiolo Cancer Institute), Tianzeng Chen(Brigham and Women's Hospital), Matthew Ho(Mayo Clinic), Xinchen Wu(Intelligent Health (United Kingdom)), Antonio Sacco(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia)
Cited by 0
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k